Proactive Investors - Run By Investors For Investors

Flex Pharma to prove technology can prevent cramping in ALS

William McVicar, President and CEO of Flex Pharma Inc (NASDAQ: FLKS) tells Proactive Investors at the BIO CEO Conference in New York, that Flex Pharma is shaping up to be an exciting year ahead.

McVicar says Flex Pharma will have clinical trials reading out in the Q1 as well as in Q3 in ALS, multiple sclerosis, and Charcot-Marie-Tooth disease. Flex Pharma will report Q4 and full year 2017 results on March 7, 2018.

View full FLKS profile View Profile

Flex Pharma Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use